Abiopharma

ANAVEX LIFE SCIENCES CORP. (AVXL) Reports the reporting period Financial Results ANAVEX LIFE SCIENCES CORP. (AVXL) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: Not disclosed
• Net Income: $7
• EPS: Not disclosed
• Cash and equivalents: 118326
  • Planned for September NEW YORK, NY, August 25, 2026
  • expected by the end of September in the ongoing Drug-drug Interaction (DDI) study. For Rett syndrome, we are moving our adult Phase 3 study forward as quickly as possible, and we have submitted a meeting request to the FDA to discuss adding pediatric patients to the study. In Fragile X syndrome, we expect to submit our IND to the FDA in September. We remain focused on the three indications that we believe demonstrate the most promising regulatory paths forward, serving both our patients and shareholders. We are taking a methodical, financially disciplined, stepwise approach to advance each of our programs along an FDA-aligned regulatory and clinical path.” Business Update, Recent and Upcoming Milestones ●The Company’s primary focus is advancing its lead compound ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment due to Alzheimer’s disease (“AD”) and mild AD (collectively known as “early AD”), and for Rett syndrome and Fragile X syndrome. These three indications are the Company’s core focus. ●Anavex will be attending the following upcoming 2026